CSE$NVO
Novo Nordisk B A/S · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Novo Nordisk reported strong Q1 2025 results with double-digit growth in both sales and profit driven by obesity and diabetes treatments.
Novo Nordisk delivered a robust Q1 2025, with sales growing 19% and net profit rising 28%, fueled by continued demand for GLP-1 therapies and expanding market presence in obesity care.
- Sales increased 19% driven by strong performance in diabetes and obesity care.
- Operating profit rose 22% supported by increased product demand and efficiency.
- North America led regional growth with a 36% increase in reported sales.
- Wegovy® and Ozempic® continued to be key growth drivers for obesity and diabetes.
Headline financials
Revenue & EPS history
Novo Nordisk · Revenue · Quarterly
$11.3B
Revenue by segment
Novo Nordisk · $272B total across 1 segment · Q4 2024
- Diabetes and Obesity care$272B—100.0%
Forward guidance
Novo Nordisk raised its full-year 2025 guidance, anticipating strong demand for GLP-1 treatments and continued international expansion.
Tailwinds
- Sales growth outlook increased to 19–27% from previous 18–26%
- Operating profit growth guidance lifted to 22–30%
- Strong global uptake of GLP-1 therapies supports outlook
- Positive trends in obesity care with Wegovy® launch in new markets
- Solid supply chain and production scalability improvements
Headwinds
- Currency headwinds expected to impact reported growth figures
- Increased R&D spending may weigh on margins
- Competitive pressures intensifying in GLP-1 market
- Regulatory uncertainties remain in international markets
- Potential reimbursement challenges in new therapeutic areas
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+31.7%
Avg return
Earnings day
+14.7%
Avg return
5 days after
+14.1%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+597.3%
Q1 2025
Best reaction
-13.9%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +556.0% | +569.8% | +533.1% | |
| Q3 2025 | -4.4% | -4.8% | -0.8% | |
| Q1 2025 | +597.3% | +3.0% | +9.0% | |
| Q4 2024 | +2.2% | +1.6% | +5.5% | |
| Q3 2024 | -0.2% | -0.9% | +0.6% | |
| Q2 2024 | -2.2% | -0.2% | +0.8% | |
| Q1 2024 | -3.9% | -1.5% | +4.7% | |
| Q3 2023 | +1.6% | +4.1% | +2.8% | |
| Q2 2023 | -2.9% | -1.3% | +4.2% | |
| Q1 2023 | -3.7% | +0.5% | -6.3% | |
| Q4 2022 | -5.1% | -0.5% | +4.4% | |
| Q3 2022 | +2.4% | +8.1% | +19.2% | |
| Q2 2022 | -9.1% | -10.5% | -10.7% | |
| Q1 2022 | +3.7% | +3.4% | -2.2% | |
| Q4 2021 | +4.9% | -0.8% | +1.5% | |
| Q3 2021 | +3.9% | +4.2% | -2.7% | |
| Q2 2021 | +0.3% | +1.9% | +2.7% | |
| Q1 2021 | +2.7% | +2.9% | +9.2% | |
| Q4 2020 | +1.1% | -0.1% | -1.9% | |
| Q3 2020 | -5.1% | +5.5% | +1.8% | |
| Q2 2020 | -3.3% | +0.2% | +0.0% | |
| Q1 2020 | -0.3% | +1.3% | +2.2% | |
| Q4 2019 | +4.4% | +3.3% | +1.6% | |
| Q3 2019 | +2.3% | +2.7% | +1.7% | |
| Q2 2019 | +3.9% | +3.2% | +3.7% | |
| Q1 2019 | -2.8% | -0.9% | -3.4% | |
| Q4 2018 | +2.7% | +3.5% | +5.5% | |
| Q3 2018 | +3.3% | -0.1% | +8.0% | |
| Q2 2018 | -5.4% | -5.8% | -4.5% | |
| Q1 2018 | +6.9% | +0.2% | +0.2% | |
| Q4 2017 | -9.1% | -10.8% | -8.6% | |
| Q3 2017 | -0.2% | -0.2% | +4.4% | |
| Q2 2017 | +0.0% | -2.1% | +2.6% | |
| Q1 2017 | +6.6% | +2.0% | +11.2% | |
| Q4 2016 | -8.4% | -9.0% | -5.5% | |
| Q3 2016 | -13.6% | -13.9% | -21.6% | |
| Q2 2016 | -13.9% | +0.6% | -20.1% | |
| Q1 2016 | -1.2% | +0.9% | -14.4% | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | -6.0% | — | — | |
| Q2 2015 | -4.5% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | -2.8% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | -3.5% | — | — | |
| Q1 2014 | +2.5% | — | — | |
| Q4 2013 | +9.5% | — | — | |
| Q3 2013 | +400.0% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro